GC Cell, founded to specialize in cell therapy, obtained approval for its developed Immunecell-LC as a liver cancer immunotherapy agent in 2007.
Immunecell-LC has now finished third-phase clinical trials on liver cancer and brain tumors (glioblastoma/GBM), and is tailed by studies, published in SCI-level journals, on its efficacy in treating liver cancer, brain tumors, and pancreatic cancer (researcher-conducted clinical trial).
The company is now researching and developing CAR-T, a next-generation cell immunotherapy agent, and, in partnership with ToolGen, a T-cell-based next-generation cancer immunotherapy agent with greater performance.
Since first introducing a blood type testing kit in Korea in 1972, GCMS went on to develop the first-ever AIDS diagnostic kit in Korea, releasing it in 1987, and following this up with the launch of a diagnostic agent for hemorrhagic fever with renal syndrome in 1990.
The company today produces over 250 types of diagnostic agents for nearly 40 diseases. It is also researching and developing advanced molecular diagnostic technology to produce more accurate and timely diagnosis of various threats to human health, including HIV and hepatitis.
Innovating health solutions based on personalized nutrition therapy
Established inSeptember 2004.
Address7F Dodam Building (Unit B), 246 Hwangsaeul-ro, Bundang-gu, Seongnam, Gyeonggi-do (7F Dodam Building (Unit B), 9-3 Sunae-dong, Bundang-gu, Seongnam, Gyeonggi-do)
ContactTel. +82-1577-5560 / Fax: +82-31-629-8601
GC Wellbeing is the result of a merger between GCJBP, which specialized in placenta-derived pharmaceuticals, GCHS, which produced natural drugs and materials, and the WB Division of GC Pharma.
GC Wellbeing today researches, develops, and produces a wide variety of personalized nutrition therapy solutions and health supplements, strengthening its position as a new leader in the personalized healthcare solutions market. The company is also researching and developing a broad array of natural drugs and health supplements.
GC LabCell, which came out of a merger between the cell therapy division of GC Pharma and the cord blood storage division of GC Labs, focuses on its strategic tasks of researching and developing Natural Killer(NK) cell-based immunotherapy agents and stem cell-based treatments for rare diseases.
The company plans to expand its business into development of more diverse stem cell-based treatments and a comprehensive range of healthcare services for the global market.
GC Genome specializes in research, development, and production of diagnostic techniques, including those for pre-pregnancy genetic analysis, cancer gene analysis, and individual responses to drugs.
With the acquisition of a next-generation genetic sequencing analyzer and a large-capacity genetic analyzer, the company will continue to research and develop cutting-edge genetic diagnostic techniques and personalized treatment solutions.
GC Healthcare provides a comprehensive range of healthcare solutions, including patient management, disease prevention, and health-strengthening services, for insurance customers, corporate clients, and international patients.
The company seeks to develop a smart healthcare system encompassing diverse services and solutions, including chronic disease management and exercise and nutrition management solutions.
GC Healthcare continues to promote greater convergence between medicine and the wellness industry by bringing together experts, services, technologies, and networks.
GC China, created under GC Pharma’s globalization strategy, produces blood fractionation products.
The company possesses advanced and quality production facilities that passed the Chinese National Health Commission’s on-site inspection in 1998 and were also the first in Anhui to obtain China’s Good Manufacturing Practice (GMP) certificate.
A biotech company accelerating the clinical development of innovative vaccine products
Established inNovember 2017.
Address1616 Eastlake Avenue East Suite 290, Seattle WA 98102
Curevo is a Seattle-based biotech company that is currently conducting clinical trials on the next-generation vaccine against varicella zoster (CRV101).
Curevo is transforming itself into a future leader of the global vaccine market, conducting clinical trials on a wide range of innovative vaccines against a variety of infectious and contagious diseases.
Through partnership with the world-class Infectious Disease Research Institute (IDRI), Curevo continues to augment its expertise.
GC Pharma launched the Mogam Institute for Biomedical Research, its nonprofit research wing, in 1984 with the proceeds it earned from Hepavax, the company’s hepatitis-B vaccine (the third successful one in the country).
The institute is tasked with promoting advances in biomedical technology, reinvesting its profits in fostering a stable and conducive environment for research. It is also the first-ever nonprofit research corporation established with the Ministry of Science and Technology (currently the Ministry of Science and ICT) in Korea.
Its main areas of research include cancer, vaccination, rare and metabolic diseases.
GC Labs, founded in 1982 as a corporation specializing in clinical research and trials, has partnered with numerous leading clinical trial institutes around the world. Its main focus is on enabling GC Pharma to achieve open innovation and distinction by adopting the latest-technology equipment, developing a highly qualified workforce, and conducting sophisticated tests with university hospitals and other advanced medical institutions.
GC Labs, housed in a state-of-the-art clinical test center with a total floor area of over 1,200 square meters—the first-ever building to be built exclusively for clinical trial purposes—continues to undertake all its tests in environments of strict control and safety. It was also the first corporate research affiliate in Korea to be awarded ISO 9001 Quality Management System and ISO 14001 Environmental Management System certification simultaneously in 2008.
The cutting-edge all-automated systems at GC Labs support the conduct and completion of over 4,000 types of tests in a precise and timely manner, around the clock. GC Labs handles the largest number of special tests in Korea.
A functional medical center dedicated to ensuring early diagnosis and improving quality of life for patients
Established inOctober 1991.
Address4F and 5F, Majesta City Tower 1, 12 Seocho-daero 38-gil, Seocho-gu, Seoul (4F and 5F, Majesta City Tower 1, 1498-5 Seocho-dong, Seocho-gu, Seoul)
ContactTel. +82-1644-0808 / Fax: +82-2-3472-0677
GC i-Med was established in 1991 with the mission of ushering in health for all through advanced diagnostic techniques and functional medicine.
The combination of cutting-edge IT systems and a care program promoting efficient health management has given birth to personalized diagnostic and healthcare services that cater to clients’ health needs throughout all stages of life.
With the help of state-of-the-art testing systems and equipment, its talented, experienced medical staff provides a wide range of medical services.
The diagnostic system based on partnerships with leading medical institutions in Korea and the U-Healthcare Program that provides thorough follow-up healthcare services make GC i-Med a topnotch center for diagnostics and functional medicine capable of providing optimal health solutions for all clients.
Korea’s one and only biotechnology engineering and construction company, capable of providing a comprehensive range of services from consultation and design to construction, inspection and auditing, and maintenance
GCEM, at the time of its foundation Korea’s only engineering and construction company specializing in biotechnology facilities, has been growing at an astonishing pace since its establishment in 2001. The company continues to lead the biotechnology facility construction market, having successfully built production and research facilities conforming to GMP and Bio-Safety Level (BSL) certification requirements.
GCEM built GC Pharma Ochang plant, the largest GMP-certified pharmaceutical plant in Korea, as well as GC Pharma Hwasun plant, Korea’s exclusive influenza vaccination production facility. In 2013, the company also successfully completed the construction of a new research facility on par with BSL 4 for the Korea Centers for Disease Control, once again proving its position as the leader and pioneer in the Korean biotech construction market.
GC Invacfarm boasts a quarantine and containment system of the highest quality in Korea. It operates a chicken farm and fertile egg production system for vaccine production according to the most rigorous quality assurance standards.
The company contributes to the growth and advancement of GCFLU as a reliable provider of quality fertilized eggs.
GC녹십자는 이메일 수집을 거부합니다
본 웹사이트에 게시된 이메일 주소가 전자우편 수집 프로그램이나 그 밖의 기술적 장치를 이용하여 무단으로 이메일 주소를 수집하는 행위를 거부하며, 이를 위반시 정보통신망 이용촉진 및 정보보호 등에 관한 법률에 의해 형사처벌됨을 유념하시기 바랍니다